Wilson Bryan: Return-to-office mandate will weaken FDA, impact hiring
Regulatory NewsJoanne S. Eglovitch
Advanced therapies/cell and gene therapyBiologics License Application (BLA)Chemistry, Manufacturing and Controls (CMC)GenericsGovernment/legislationHealth Authority meeting and communication strategyLeadershipMedical DevicesPharmaceuticalsProject managementRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)